Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 107, Issue 1, 2013, Pages 51-58

  Moi, Meng Ling ^a   Takasaki, Tomohiko ^a   Saijo, Masayuki ^a   Kurane, Ichiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Antibody dependent enhancement; Dengue; Dengue haemorrhagic fever; Fc R expressing cells; Secondary infection

Indexed keywords

FC RECEPTOR; NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DENGUE; FEMALE; HAMSTER; HEMODILUTION; HUMAN; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; SECONDARY INFECTION; SEROTYPE; VIRUS ISOLATION; ANTIBODY DEPENDENT ENHANCEMENT; BLOOD; CELL LINE; DENGUE VIRUS; IMMUNOLOGY; PATHOGENICITY; SERODIAGNOSIS; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; DENGUE; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; HUMANS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS;

MLCS; MLOWN;

EID: 84880475143     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/trs007     Document Type: Article

References (30)

1. Graham RR, Juffrie M, Tan R. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia. I. Studies in 1995-1996. Am J Trop Med Hyg 1999;61:412-9.
2. Sangkawibha N, Rojanasuphot S, Ahandrik S et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984;120:653-69.
3. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-81.
4. Kou Z, Quinn M, Chen H et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol 2008;80:134-46.
5. Littaua R, Kurane I, Ennis FA. Human IgG Fc Receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 1990;144:3183-86.
6. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988;38:411-9.
7. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989;40:444-51.
8. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181:2-9.
9. Wang WK, Chen HL, Yang CF et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis 2006;43:1023-30.
10. Moi ML, Lim CK, Takasaki T, Kurane I. Involvement of the Fcg receptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection. J Gen Virol 2010;91:103-11.
11. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM et al. Immature dengue virus: a veiled pathogen. Plos Pathogens 2010;6:e1000718.
12. Ito M, Takasaki T, Yamada K et al. Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 2004;42:5935-7.
13. Ito M, Yamada K, Takasaki T et al. Phylogenetic analysis of dengue viruses isolated from imported dengue patients: possible aid for determining the countries where infections occurred. J Travel Med 2007;14:233-44.
14. Moi ML, Lim CK, Kotaki A et al. Detection of higher levels of dengue viremia using FcgR-expressing BHK-21 cells than FcgR-negative cells in secondary Infection but not in primary infection. J Infect Dis 2011;203:1405-14.
15. WHO. Dengue guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization; 2009. whqlibdoc.who. int/publications/2009/9789241547871_eng.pdf [accessed 6 August 2012]
16. Roehrig J. Guidelines for plaque reduction neutralizing testing of human antibodies to dengue viruses. Geneva: World Health Organization; 2007. whqlibdoc.who.int/hq/2007/who_ivb_07.07_eng. pdf [accessed 6 August 2012]
17. Moi ML, Lim CK, Chua KB et al. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcgR-expressing cells. PLoS Negl Trop Dis 2012;6:e1536.
18. Vanlandingham DL, Schneider BS, Klingler K et al. Real-time reverse transcriptase-polymerase chain reaction quantification of West Nile virus transmitted by Culex pipiens quinquefasciatus. Am J Trop Med Hyg 2004;71:120-3.
19. Vazeille M, Mousson L, Martin E, Failloux AB. Orally co-Infected Aedes albopictus from La Reunion Island, Indian Ocean, can deliver both dengue and chikungunya infectious viral particles in their saliva. PLoS Negl Trop Dis 2010;4:e706.
20. Konishi E, Tabuchi Y, Yamanaka A. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J Virol Methods 2010;163:360-7.
21. Halstead SB. Dengue. London: Imperial College Press. Tropical Medicine, Science and Practice series, vol 5. 2008.
22. Beltramello M, Williams KL, Simmons CP et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010;8:271-83.
23. Schieffelin JS, Costin JM, Nicholson CO et al. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 2010;7:28.
24. Guy B, Chanthavanich P, Gimenez S et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004;22:3563-74.
25. Laoprasopwattana K, Libraty DH, Endy TP et al. Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 2005;192:510-9.
26. Ito M, Mukai RZ, Takasaki T et al. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus. Arch Virol 2010;155: 1617-24.
27. Diamond MS, Edgil D, Roberts TG et al. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol 2000;74:7814-23.
28. Morens DM, Halstead SB, Marchette NJ. Profiles of antibodydependent enhancement of dengue virus type 2 infection. Microb Pathog 1987;3:231-7.
29. Kochel TJ, Watts DM, Halstead SB et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002;360:310-2.
30. Rodrigo WW, Alcena DC, Kou Z et al. Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin Vaccine Immunol 2009;16:285-7.